Equities Analysts Set Expectations for MIST Q3 Earnings

Posted by Brian Himes on Aug 14th, 2026

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Investment analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.22) per share for the quarter, down from their prior forecast of ($0.19). The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.82) EPS, FY2029 earnings at $1.01 EPS and FY2030 earnings at $1.69 EPS.

MIST has been the topic of several other reports. Wells Fargo & Company dropped their price target on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.25.

View Our Latest Stock Analysis on Milestone Pharmaceuticals

Milestone Pharmaceuticals Stock Down 4.9%

Shares of NASDAQ:MIST opened at $1.07 on Friday. Milestone Pharmaceuticals has a 52 week low of $1.00 and a 52 week high of $3.06. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.09 and a current ratio of 9.18. The company has a market cap of $133.22 million, a PE ratio of -1.55 and a beta of 0.98. The firm has a 50 day simple moving average of $1.23 and a 200 day simple moving average of $1.52.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.82 million.

Institutional Trading of Milestone Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Orbimed Advisors LLC bought a new stake in Milestone Pharmaceuticals in the 3rd quarter valued at $6,444,000. Marshall Wace LLP lifted its position in shares of Milestone Pharmaceuticals by 289.8% during the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock worth $3,347,000 after buying an additional 1,231,793 shares during the period. Pathstone Holdings LLC bought a new stake in Milestone Pharmaceuticals in the third quarter valued at $2,000,000. Two Sigma Investments LP bought a new position in shares of Milestone Pharmaceuticals during the third quarter valued at $1,333,000. Finally, Millennium Management LLC acquired a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth about $803,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.